IBDEI0XR ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16665,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,16665,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,16665,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,16666,0)
 ;;=451.9^^92^940^121
 ;;^UTILITY(U,$J,358.3,16666,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16666,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,16666,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,16666,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,16667,0)
 ;;=446.6^^92^940^122
 ;;^UTILITY(U,$J,358.3,16667,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16667,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,16667,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,16667,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,16668,0)
 ;;=286.4^^92^940^125
 ;;^UTILITY(U,$J,358.3,16668,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16668,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,16668,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,16668,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,16669,0)
 ;;=204.00^^92^940^1
 ;;^UTILITY(U,$J,358.3,16669,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16669,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,16669,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,16669,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,16670,0)
 ;;=204.01^^92^940^3
 ;;^UTILITY(U,$J,358.3,16670,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16670,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,16670,1,5,0)
 ;;=5^ALL,In Remission
 ;;^UTILITY(U,$J,358.3,16670,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,16671,0)
 ;;=204.10^^92^940^16
 ;;^UTILITY(U,$J,358.3,16671,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16671,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,16671,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,16671,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,16672,0)
 ;;=204.11^^92^940^18
 ;;^UTILITY(U,$J,358.3,16672,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16672,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,16672,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,16672,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,16673,0)
 ;;=201.90^^92^940^83
 ;;^UTILITY(U,$J,358.3,16673,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16673,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,16673,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,16673,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,16674,0)
 ;;=785.6^^92^940^89
 ;;^UTILITY(U,$J,358.3,16674,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16674,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,16674,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,16674,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,16675,0)
 ;;=200.20^^92^940^90
 ;;^UTILITY(U,$J,358.3,16675,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16675,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,16675,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,16675,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,16676,0)
 ;;=202.00^^92^940^92
 ;;^UTILITY(U,$J,358.3,16676,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16676,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,16676,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,16676,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,16677,0)
 ;;=200.10^^92^940^91
 ;;^UTILITY(U,$J,358.3,16677,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16677,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,16677,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,16677,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,16678,0)
 ;;=273.3^^92^940^93
 ;;^UTILITY(U,$J,358.3,16678,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16678,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,16678,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,16678,2)
 ;;=^73013
